壳交联pH响应型PLGA载药微球的制备与研究

首先采用一次乳化法制备出PLGA[聚(乳酸-羟基乙酸)]纳米微球,并通过静电吸附将阳离子聚合物壳聚糖修饰到PLGA微球表面,然后以香草醛为交联剂对壳聚糖进行化学交联,得到一种壳交联的p H响应型纳米微球(PCV),微球粒径为(277.60±38.01)nm,表面电位为(21.60±4.51)m V.微球稳定性评价结果显示微球在24 h内粒径变化较小;流式细胞仪检测显示细胞对PCV微球的摄取量比未经修饰的PLGA微球的摄取量高;空白微球细胞毒性实验表明在空白微球浓度小于80μg/m L时细胞的存活率达93.24%.以多西他赛(DTX)为模型药物进行包载,该纳米微球DTX的载药率为7.48%,包封率为34.98%;体外药物释放实验显示,该微球在p H=5.0环境下孵育90 h的药物积累释放率达58.66%,而在p H=7.4的环境下的药物积累释放率为50.63%;此外,载DTX微球毒性试验结果表明该载药微球对A549肺癌细胞有较强的杀伤作用,其IC50值可达0.0009μg/m L.     

PLA/MSM缓释微球的制备及生物活性

采用膜乳化-液中干燥法制备出担载二甲基砜(MSM)的聚乳酸(PLA)微球(PLA/MSM), 并研究了膜孔径、 搅拌转速和MSM浓度对载药微球形貌、 尺寸、 载药量、 体外释放及细胞活性的影响; 采用场发射环境扫描电子显微镜(ESEM)观察微球形貌、 尺寸及分布, 用等离子体发射光谱(ICP-AES)法检测PLA/MSM微球载药量、 包封率及体外释放, 采用ESEM观察微球内部结构, 并通过体外细胞培养和噻唑蓝(MTT)法检测MC-3T3-E1细胞的增殖能力. 研究结果表明, 膜乳化法制备的载药微球规整, 呈典型的圆球状, 表面光滑, 内部有多孔结构. 当膜孔径为5.1 μm且搅拌转速为500 r/min时, PLA/MSM微球大小更为均一; 当体系中MSM质量分数为8.6%时, 载药量可达到77.43%. 随着膜孔径减小及药物浓度的增加, 体外释放速率加快, 但初期均无明显的突释现象, 约10 d后累积释放量达到89.2%. 细胞实验结果显示, 在膜孔径为5.1 μm且MSM质量分数为8.6%的条件下, 制备的载药微球在细胞培养7 d时表现出明显的促增殖作用.     

氟尿嘧啶-壳寡糖/硒纳米微球的制备及抑制肿瘤细胞生长活性

为研究抗肿瘤药物与辅药负载于同一药物载体的作用效果, 首先以壳寡糖和广谱抗肿瘤药物5-氟尿嘧啶(5-Fu)为原料通过化学键合合成氟尿嘧啶-壳寡糖前体, 然后以其为模板通过溶胶-凝胶法制备了同时负载氟尿嘧啶和硒纳米颗粒的壳寡糖微球. 采用透射电子显微镜(TEM)、 Zeta电位仪和红外光谱(IR)对制备的微球进行了表征, 结果表明, 微球粒径为433 nm, 硒纳米颗粒包裹在微球内; 对微球包裹药物进行检测发现, 5-Fu装载率为(8.2±0.3)%, 硒装载率为(7.96±0.34)%; 体外缓释检测和细胞实验结果证实, 微球能够缓慢释放2种药物, 其缓释作用能很好地抑制肝癌细胞SMMC-7721的生长.     

微乳液成核-离子交联制备阿司匹林/壳聚糖纳米微球及其体外释放行为

以自制阿司匹林为药物模型,壳聚糖(CS)为载体源,采用微乳液成核-离子交联法制备了阿司匹林/壳聚糖纳米缓释微球.分别用傅里叶变换红外(FTIR)光谱、场发射扫描电子显微镜(FESEM)、透射电子显微镜(TEM)、动态激光光散射(DLLS)、X射线粉末衍射(XRD)等表征了纳米微粒的化学组成、外观形貌、平均粒径和粒径分布、微球中壳聚糖的晶体结构以及阿司匹林的分布形态.结果表明,利用微乳液成核-离子交联法制备的阿司匹林/壳聚糖微球平均粒径约为88nm且粒径分布均匀,成核后壳聚糖结晶形态基本未变,阿司匹林以分子形态分布于微粒中,分子间未形成堆砌,为无定形态.采用UV-Vis分光光度计考察了微球的药物包封率、载药量,并对微球在生理盐水和葡萄糖溶液中的释药行为进行跟踪.结果表明,微球的载药量可达55%,药物包封率可达42%,实验条件下具有较好的药物缓释作用.     

负载阿霉素的丝蛋白纳米微球

丝蛋白具有良好的生物相容性, 生物可降解性以及无免疫原性. 利用丝蛋白独特的亲疏水多嵌段共聚物结构特征和构象转变机制, 通过乙醇诱导和冷冻相结合的自组装方法制备得到丝蛋白纳米微球后, 再在纳米微球表面包覆阿霉素, 成功获得了负载阿霉素的丝蛋白纳米载药微球. 该载药丝蛋白纳米微球的尺寸为350～400 nm, 具有圆球形态并且分散性能良好; 其载药率为4.6%, 包封率大于90%, 在磷酸缓释溶液中的释放可达7天以上. 此外, 研究发现其缓释行为具有pH响应性, 在pH=5.0的磷酸缓冲溶液中的缓释量明显大于在pH=7.4的缓冲液中. 体外细胞培养结果显示, 纯丝蛋白纳米微球基本没有细胞毒性; 而负载有阿霉素的丝蛋白纳米微球能明显抑制癌细胞(Hela细胞)的增殖, 且24 h和48 h的培养结果表现出与单纯药物相同的药效. 因此, 该负载阿霉素的丝蛋白纳米微球在临床癌症淋巴化疗方面具有潜在的应用价值.     

冬凌草甲素卟啉壳聚糖微球的制备及体外光动力抗肿瘤活性研究

基于光-化联合抗肿瘤的目的,通过共价偶联将5-对(6-溴已氨基苯基)-10,15,20-三苯基卟啉(BHP)引入壳聚糖侧基制备复合物,卟啉枝接率平均达30.80%;采用乳化交联法制备了冬凌草甲素卟啉壳聚糖微球,经高效液相色谱(HPLC)测得微球载药量为12.41%,包封率为8.72%,48 h体外释放量达81.74%;采用噻唑蓝(MTT)法考察合成的系列化合物对人乳腺癌细胞MCF-7的光毒性.实验结果表明:浓度为25,50和100μmol/m L的冬凌草甲素光敏微球光照30min后对MCF-7细胞的光动力杀伤率的平均值分别达(31.55±1.70)%,(71.03±0.76)%和(82.74±0.38)%,光动力杀伤效果显著.     

肾上腺髓质素微球复合PLGA/纳米羟基磷灰石支架材料的制备及生物活性评价

利用离子乳化交联法制备了负载肾上腺髓质素的壳聚糖微球,应用热致相分离法制备了乳酸和乙醇酸共聚物/纳米羟基磷灰石(PLGA/nHA)支架材料并在其中包覆载药微球.通过扫描电子显微镜、体外释放行为、材料溶血行为、碱性磷酸酶(ALP)活性的测定、支架材料表面细胞荧光染色和MTT[3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐]比色法等手段综合评价载药支架材料的性能及生物活性.结果表明,微球直径均匀,载药支架孔径大小合适并相互穿通.支架材料的溶血率小于5%,符合医用材料的溶血实验要求.载药支架及支架材料本身对成骨细胞及血管内皮细胞的增殖以及成骨细胞的分化均有一定的促进作用.     

阿司匹林-蒙脱土-壳聚糖缓释微球的制备及其体外释放性能

利用溶液法预先制备壳聚糖(Cs)-蒙脱土(MMT)复合材料(Cs-MMT),以Cs-MMT、Cs为原料,采用反相悬浮聚合法制得一种新型药物缓释体系阿司匹林-蒙脱土-壳聚糖载药微球(Asp-MMT-Cs)。采用FT-IR、SEM表征了Cs-MMT和Asp-MMT-Cs载药微球的结构及形态;设计正交实验优化了Asp-MMT-Cs载药微球的制备工艺;通过体外释放实验探讨了载药微球在不同模拟释放液中的释药规律。结果表明:所得微球球形度好,粒径分布较均匀;最优工艺制得的载药微球平均粒径为81.20μm,载药量为9.61%,包封率为76.78%。该缓释体系具有pH敏感性,更倾向于在pH较高的磷酸盐缓冲溶液中释放。     

生物降解聚酯包埋利福平缓释微球的制备及释放行为

以生物可降解乙交酯和丙交酯的无规共聚物(PLGA)为载体,将抗结核病药利福平溶解于PLGA的有机溶液中,采用通常乳化-溶剂挥发方法制备了药物缓释微球.研究了影响微球制备的工艺条件.用电子显微镜观察了微球及降解后的表面形态,测定了微球粒径及载药量,评价了载药微球的体外释放行为.结果表明,以质量分数为1%的明胶为稳定剂,制备的微球形态完整,粒径范围为10～30μm,微球中利福平的平均质量分数为24.3%.体外释药时间可以通过高分子的降解速率来调控,本实验的释药时间可以在42～84d之间调控,药物缓释达到了理想的零级动力学释放.因此,利福平PLGA微球具有显著的长效、恒量药物缓释作用.     

聚[碳酸(亚丁酯-co-ε-己内酯)酯]的制备及其载药微球性能的研究

采用阴离子配位聚合方法, 合成了二氧化碳、1,2-环氧丁烷与ε-己内酯的三元共聚物: 聚[碳酸(亚丁酯-co-ε-己内酯)酯](PBCL). 并采用复相乳液(W/O/W)溶剂挥发法制备了包裹抗菌药物甲磺酸帕珠沙星的可降解微球. 对聚合物进行了FTIR, ¹H NMR, ¹³C NMR, DSC, TGA和WAXD等表征, 以及降解性能和载药微球特性的研究. 结果表明, PBCL热稳定性及降解性能优于聚碳酸亚丁酯(PBC). 所得PBCL微球球形规整、表面光滑. 大部分微球粒径在0.5～1 μm的范围内, 载药量和包封率分别达到38.21%和87.9%. 微球的体外释药性能研究在pH 7.4的磷酸缓冲溶液中进行, 释放21 d后, PBCL微球的累积释药量为84.74%, PBC微球的释药量仅为17.29%. 药物的体外释放行为符合Higuchi方程. PBCL载药微球具有长效缓释作用.     

Surface modification of Mitoxantrone-loaded PLGA nanospheres with chitosan

The purpose of this research was to develop polylactic-co-glycolic acid (PLGA) nanospheres surface modified with chitosan (CS). Mitoxantrone- (MTO-) loaded PLGA nanospheres were prepared by a solvent evaporation technique. The PLGA nanospheres surface was modified with CS by two strategies (adsorption and covalent binding). PLGA nanospheres of 248.4 ± 21.0 nm in diameter characterized by the laser light scattering technique, scanning electron microscopy (SEM) are spherical and its drug encapsulation efficiency is 84.1 ± 3.4%. Zeta potential of unmodified nanospheres was measured to be negative −21.21 ± 2.13 mV. The positive zeta potential of modified nanospheres reveals the presence of CS on the surface of the modified nanospheres. Modified nanospheres were characterized for surface chemistry by X-ray photoelectron spectroscopy (XPS) and Fourier transform infrared (FT-IR). FT-IR spectra exhibited peaks at 3420 cm⁻¹ and 1570 cm⁻¹, XPS spectra shows the N 1s (atomic orbital 1s of nitrogen) region of the surface of the nanospheres, corresponding to the primary amide of CS. In vitro drug release demonstrated that CS-modified nanospheres have many advantages such as prolonged drug release property and decreased the burst release over the unmodified nanospheres, and the modified nanospheres by covalent binding method could achieve the release kinetics of a relatively constant release. These data demonstrate high potential of CS-modified PLGA nanospheres for the anticancer drug carrier.     

Chitosan-coated magnetic nanoparticles as carriers of 5-Fluorouracil: Preparation,characterization and cytotoxicity studies

The chitosan-coated magnetic nanoparticles (CS MNPs) were prepared as carriers of 5-Fluorouracil (CS–5-Fu MNPs) through a reverse microemulsion method. The characteristics of CS–5-Fu MNPs were determined by using transmission electron microscopy (TEM), FTIR spectroscopy and vibrating-sampling magnetometry (VSM). It was found that the synthesized CS–5-Fu MNPs were spherical in shape with an average size of 100 ± 20 nm, low aggregation and good magnetic responsivity. Meanwhile, the drug content and encapsulation rate of the nanoparticles was 16–23% and 60–92%, respectively. These CS–5-Fu MNPs also demonstrated sustained release of 5-Fu at 37 °C in different buffer solutions. The cytotoxicity of CS–5-Fu MNPs towards K562 cancer cells was investigated. The result showed that CS–5-Fu MNPs retained significant antitumor activities. Additionally, it was observed that the FITC-labeled CS–5-Fu MNPs could effectively enter into the SPCA-1 cancer cells and induced cell apoptosis.     

装载吲哚美辛肝素类纳米胶束的制备及抗凝作用

肝素(hep)作为一种抗凝剂,在临床医学上广泛应用。 本文以肝素为亲水段、去氧胆酸(DOCA)为疏水段合成了一种肝素类两亲性的聚合物(hep-DOCA,HD),并通过水相自组装方法,制备纳米胶束(HD-IDM),装载具有抗血栓作用的吲哚美辛(IDM),协同实现材料的抗凝血功能。 通过动态光散射、Zeta电势和透射电子显微镜(TEM)等技术手段表征了纳米胶束结构和性能。 当纳米胶束载药量为0.0913 mg/mL时,载药纳米胶束浓度为0.4 g/L,此时细胞存活率为92.81%,溶血率为0.83%,表明载药胶束具有良好的生物相容性。 肝素钠,hep-DOCA和HD-IDM的全血凝血指数分别为86.48%、77.47%和89.53%,全血凝血时间分别为927、837和965 s,血栓凝块实验中产生的血栓质量分别为0.11、0.20和0.07 g,证明载药纳米胶束具有优良的抗凝血效果。     

Cd2+ Counterion-Assisted Synthesis of Uniform CdS Nanospheres Capped with the Anionic Surfactant Sodium dodecylsulfate

Uniform cadmium sulfide (CdS) nanospheres were successfully prepared in the presence of the anionic surfactant sodium dodecylsulfate (SDS) at an appropriate concentration and relatively low temperature. Zeta potential data were collected for the three kinds of CdS particles to verify the existence of the Cd²⁺counterion on the CdS surface and Charge reversal; this was crucial for the explanation of how the anionic SDS surfactant molecules adsorbed on the negatively charged surface. Moreover, we confirmed that SDS had coated the surface of CdS nanospheres using infrared spectroscopy, and thermogravimetric analysis. An counterion assisted mechanism accounting for synthesis of CdS nanospheres could be widely used in the synthesis of nanomaterials if there is specific adsorption of the counterion. The CdS nanospheres showed good performance for the rapid adsorption of methylene blue.     

5-氟尿嘧啶在pH敏感型分子筛控释载体中的缓释行为

以肠溶性的羟丙基甲基纤维素邻苯二甲酸酯(HPMCP)作为包覆材料,制备了HPMCP包覆的SBA-15介孔分子筛药物控释载体(HPMCP/SBA-15),并考察了抗癌药物5-氟尿嘧啶(5-Fu)负载于控释载体后,在不同pH释放环境中的释放行为.结果表明,在模拟胃液中(pH=1.2),HPMCP能明显地延缓5-Fu的释放速度;药物释放4h后,其释放率仅为15%.而在模拟肠液中(pH=7.5)HPMCP迅速溶解,对5-Fu释放速度的影响甚微;药物释放4h后,释放率可达到80%.与此同时,包覆膜的干燥温度影响5-Fu的释放行为,干燥温度越高,药物在模拟胃液中的释放速度越慢.     

“Dissolution-reassembly” for N-doped hollow micro/meso-carbon spheres with high supercapacitor performance

N-Doped hollow carbon spheres with mesoporous/microporous shells and outstanding performance in supercapacitor has been prepared by “dissolution-reassembly” method.     

Enhancement adsorption of hexavalent chromium from aqueous solution on polypyrrole using ethylamine group

A novel nanospheres adsorbent was successfully prepared using functionalized 1H-Pyrrole-1-ethanamine by homopolymerization. It could be easily protonated to form double-charged repeating structural units on the surface of nanospheres. The physic-chemical properties were characterized by SEM, TGA, XPS and Zeta potential. The effects of initial pH, adsorbent dosage, contact time, initial concentration, and ionic strength were studied in detail. The maximum adsorption capacity of Chromium(VI) was about 729.09?mg?g^?1 at room temperature. Electrostatic attraction played an important role in the adsorption process and the size of the ion group had a greater effect on the adsorption performance than the charge.     

酯化淀粉乳化剂制备的高效氯氟氰菊酯O/W乳液的稳定机制

通过测定辛烯基琥珀酸淀粉钠的用量、盐离子、pH值和温度等因素对油滴Zeta电位及表面吸附量的影响,分析了以酯化淀粉辛烯基琥珀酸淀粉钠为乳化剂制备的5％高效氯氟氰菊酯水乳剂的稳定机制.结果表明,辛烯基琥珀酸淀粉钠质量分数为7％时,Zeta电位达到最大值,油滴表面吸附量接近饱和;Na+、Mg2+和Al3+压缩油滴表面的双电层,降低Zeta电位,削弱静电排斥作用,增加辛烯基琥珀酸淀粉钠分子柔性,提高辛烯基琥珀酸淀粉钠表面吸附量,且随着Na+、Mg2、Al3+离子强度依次增大,压缩双电层能力依次增强,Zeta 电位降低和表面吸附量增加程度依次增大;pH值影响辛烯基琥珀酸淀粉钠在水中的解离,在碱性范围内解离出较多羧酸根,静电排斥力较大,Zeta电位较高,但表面吸附量有所降低;温度升高,辛烯基琥珀酸淀粉钠在水溶液中溶解度增大,呈舒展状态,且辛烯基琥珀酸淀粉钠从油滴表面逃逸的趋势增加,油滴表面Zeta电位和表面吸附量均随着温度升高而降低,在低温区差别不大,温度越高二者变化越明显.辛烯基琥珀酸淀粉钠通过吸附于油滴表面为其提供较强的静电斥力和空间位阻作用而维持O/W乳液稳定.     

Low cost,high performance supercapacitor electrode using coconut wastes: eco-friendly approach

Low cost, high performance supercapacitor electrodes were fabricated using coconut waste as precursor. Simple one step pyrolysis is adopted to get the spherical shaped particle where lignocellulosic nature of carbon converts into porous carbon nanospheres. Three types of coconut wastes, namely, coconut fiber(CF), coconut leaves(CL) and coconut stick(CS) have been studied and compared for their application in supercapacitors. Uniform spherical shape with particle size ranging from 30 to 60 nm for leaves and sticks and ~20 nm for fibers was obtained. The electrochemical properties of the porous carbon nanospheres were studied using cyclic voltammetry(CV), chronopotentiometry(CP) and electrochemical impedance spectroscopy(EIS). The porous carbon nanospheres derived from all the three biowaste samples show good electrochemical performance for supercapacitor application. Porous carbon nanospheres derived from coconut fiber exhibited maximum specific capacitance of 236 F/g followed by coconut stick and coconut leaves with 208 and 116 F/g respectively at a scan rate of 2 m V/s. Further impedance studies showed a charge transfer resistance of 4.9 for the porous carbon nanospheres derived from coconut fiber, while those from coconut leaves and coconut stick exhibited a slightly higher resistance of 6 and14.2, respectively. The simple eco-friendly approach we have demonstrated for synthesizing coconut waste based carbon nanospheres makes them excellent candidates for future, low-cost, energy storage devices.